Trial Profile
Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lorukafusp alfa (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Jan 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Oct 2007 Status changed from recruiting to suspended.
- 26 Aug 2005 New trial record.